FibroGen, Inc. (NASDAQ:FGEN) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC increased its position in shares of FibroGen, Inc. (NASDAQ:FGEN) by 3.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,083,521 shares of the biopharmaceutical company’s stock after purchasing an additional 32,884 shares during the period. Geode Capital Management LLC owned 1.08% of FibroGen worth $433,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in FGEN. Point72 DIFC Ltd raised its holdings in FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares during the period. Doheny Asset Management CA purchased a new stake in FibroGen in the second quarter valued at approximately $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in FibroGen in the second quarter valued at approximately $130,000. Sei Investments Co. lifted its stake in FibroGen by 38.4% during the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 41,442 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of FibroGen during the second quarter worth $145,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Trading Down 5.3 %

NASDAQ:FGEN opened at $0.62 on Monday. FibroGen, Inc. has a 12-month low of $0.18 and a 12-month high of $2.93. The firm has a market cap of $62.07 million, a PE ratio of -0.50 and a beta of 0.75. The stock has a fifty day moving average price of $0.42 and a 200 day moving average price of $0.50.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the previous year, the business posted ($0.52) EPS. Equities analysts forecast that FibroGen, Inc. will post -0.86 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on FGEN. StockNews.com began coverage on FibroGen in a report on Wednesday, January 1st. They issued a “hold” rating on the stock. William Blair reissued a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. Finally, HC Wainwright raised shares of FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.